Earnings ·
Agios Pharmaceuticals reported second quarter 2026 results with worldwide net revenues of $44.7 million, driven by a…
AGIOAgios Pharmaceuticals, Inc.
Agios Pharmaceuticals reported second quarter 2026 results with worldwide net revenues of $44.7 million, driven by a strong U.S. commercial launch of AQVESME in thalassemia and ex-U.S. sales of PYRUKYND. The company recorded a net loss of $100.7 million, an improvement from the $112.0 million loss in the prior year period. R&D expenses increased to $100.8 million due to a $25.0 million upfront payment for the cevidoplenib license agreement with Oscotec. The FDA granted Priority Review for the supplemental New Drug Application of mitapivat for sickle cell disease, setting a PDUFA goal date of November 1, 2026. Agios holds $964.8 million in cash and marketable securities as of June 30, 2026. The company operates in the biopharmaceutical industry, developing innovative medicines for rare diseases.